
AstraZeneca investors balk at potential Bristol Myers mega-merger
Investors wiped 6.7% off AstraZeneca’s share price Monday morning following reports of preliminary merger talks with Bristol Myers Squibb. The proposed combination of the two pharmaceutical giants, which would create a near $400 billion entity, faced immediate skepticism from market analysts questioning the strategic necessity of such an acquisition.


























